Background: Asthma exacerbations lead to frequent emergency visits and hospitalizations,
and are associated with high morbidity and occasionally mortality. New therapeutic …

Objective To determine the ability of budesonide via an inhaler (Pulmicort Turbuhaler; Astra
Draco AB) to replace oral glucocorticosteroids (GCSs) in adult subjects with moderate-to …

The efficacy of nebulized budesonide (0.5 mg bid) against placebo was evaluated in the
management of asthma in 23 infants, aged 3 to 17 months, using a double blind crossover …

The relative clinical efficacy and systemic effects of different inhaled corticosteroids is
controversial. To obtain further information on this matter, the authors have performed meta …

We have demonstrated recently that 1 year of regular inhaled budesonide use can produce
substantial improvements in airway responsiveness accompanied by significant …

Airway inflammation is a major contributing factor in both asthma and chronic obstructive
pulmonary disease (COPD) and represents an important target for treatment. Inhaled …

Objective: To determine the efficacy and safety of budesonide delivered by an inhalation-
driven dry powder inhaler (Turbuhaler) in children with moderate to severe persistent …

The optimal treatment for mild asthma is uncertain. We assessed the effects of adding a long-
acting inhaled beta-agonist, formoterol, to low doses of an inhaled corticosteroid …

Background In patients with mild asthma, as-needed use of an inhaled glucocorticoid plus a
fast-acting β2-agonist may be an alternative to conventional treatment strategies. Methods …

Budesonide by inhalation and placebo were tested in 18 patients with moderate chronic
bronchial asthma. Three dose levels of budesonide were used (25, 100 and 400 μg qid) and …